Weight Loss Pill Shows 16% Loss in New Study

Millions of people who struggle with weight but fear needles just got promising news from a clinical trial.

Structure Therapeutics announced Monday that their experimental daily pill led patients to lose about 16% of their body weight over 44 weeks, compared to those taking a placebo. That's significantly better than the 11% weight loss seen with Eli Lilly's similar pill in a longer 72-week trial.

The results position the small biotech company to compete against pharmaceutical giants Eli Lilly and Novo Nordisk in the race to create pill versions of popular GLP-1 injections like Ozempic and Wegovy. Those injections have helped millions lose weight but require weekly shots that many people avoid.

The study tested the drug for 44 weeks, showing patients could achieve substantial weight loss in less time than competing medications. Lilly's oral drug orforglipron is expected to receive FDA approval in the coming weeks, while Novo Nordisk launched an oral version of Wegovy late last year.

Converting these medications from injections to pills could transform obesity treatment. Many patients stop using effective weight loss injections simply because they dislike needles or find the weekly ritual inconvenient.

The Ripple Effect

This advancement could reach far beyond the patients in the study. More than 40% of American adults live with obesity, facing increased risks of heart disease, diabetes, and other serious health conditions.

Pills are easier to store, carry, and take than injections. They don't require refrigeration or special disposal containers. For people who travel frequently or have unpredictable schedules, a daily pill fits more seamlessly into everyday life.

The competition between multiple companies developing oral versions also creates pressure to improve effectiveness and reduce costs. When Lilly reported their results last year, it set a benchmark that Structure Therapeutics has now exceeded.

These Phase 2 results represent a middle stage of testing, meaning the drug still needs larger trials to prove its safety and effectiveness before reaching pharmacies. But the strong performance suggests patients may soon have multiple pill options for weight management.

The path from promising trial results to actual treatment takes time, but each advancement brings accessible obesity care closer to reality for millions.